AI assistant
Lineage Cell Therapeutics Inc. — Director's Dealing 2018
Sep 13, 2018
6895_dirs_2018-09-13_04aa86ca-32ba-4cb4-a2dc-94993c61e400.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOTIME INC (BTX)
CIK: 0000876343
Period of Report: 2018-09-11
Reporting Person: ANDREWS DEBORAH J (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-09-11 | Common Shares, no par value | P | 1604 | $2.35 | Acquired | 10000 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Option to Purchase Common Shares | $2.06 | 2023-06-30 | Common Shares (40000) | 40000 | Direct |
| Option to Purchase Common Shares | $3.15 | 2022-06-30 | Common Shares (20000) | 20000 | Direct |
| Option to Purchase Common Shares | $2.72 | 2021-06-30 | Common Shares (20000) | 20000 | Direct |
| Option to Purchase Common Shares | $3.57 | 2020-06-30 | Common Shares (20000) | 20000 | Direct |
| Option to Purchase Common Shares | $3.11 | 2019-06-30 | Common Shares (20000) | 20000 | Direct |
| Option to Purchase Common Shares | $2.86 | 2019-04-10 | Common Shares (20000) | 20000 | Direct |
Footnotes
F1: Will become exercisable on June 30, 2019, based upon continued service on the board of directors.
F2: Became exercisable in four equal quarterly installments after the date of grant on July 1, 2017.
F3: Became exercisable in four equal quarterly installments after the date of grant on July 1, 2016.
F4: Became exercisable in four equal quarterly installments after the date of grant on July 1, 2015.
F5: Became exercisable in four equal quarterly installments after the date of grant on July 1, 2014.
F6: Became exercisable in four equal quarterly installments after the date of grant on April 11, 2014.